Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:07 PM ET 8-K
Clinical Trial Data Contineum Therapeutics, Inc. CTNM

Contineum Therapeutics Clinical Trial Data

Contineum Therapeutics reported that the Phase 2 MOONLIGHT-1 trial of JNJ-5120/PIPE-307 for major depressive disorder did not meet its primary efficacy endpoint of improvement in the MADRS total score. The drug candidate, which is being developed under a global license agreement with Johnson & Johnson, was well-tolerated with no new safety signals. Johnson & Johnson is currently evaluating the full data set, including exploratory endpoints, to determine the next steps for the program.

Counterparty
Johnson & Johnson
4:05 PM ET 8-K
M&A Deal CPI Card Group Inc. PMTS

CPI Card Group M&A Deal with Tricor Pacific Capital Partners

CPI Card Group Inc. announced the closing of a secondary public offering of 2,687,921 shares of common stock by selling stockholders Tricor Pacific Capital Partners. The offering included the full exercise of the underwriters' option to purchase additional shares, and the company received zero proceeds from the sale as it was entirely a resale of shares by existing holders.

Counterparty
Tricor Pacific Capital Partners (Fund IV)
4:02 PM ET 8-K
Capital Raise Yarrow Bioscience, Inc. YARW

Yarrow Bioscience Capital Raise of $172M

Yarrow Bioscience entered into an underwriting agreement to sell 5,769,231 shares of common stock at $26.00 per share. The underwriters fully exercised their option to purchase an additional 865,384 shares, bringing the total expected net proceeds to approximately $161.8 million after expenses.

Value
$172M
Counterparty
Jefferies LLC, TD Securities (USA) LLC and Guggenheim Securities, LLC
4:01 PM ET 8-K
Clinical Trial Data Moleculin Biotech, Inc. MBRX

Moleculin Biotech Clinical Trial Data

Moleculin Biotech announced that new data on its lead drug candidate, Annamycin (naxtarubicin), will be presented at three scientific venues in September 2026, including the AACR Conference on Pancreatic Cancer. The presentations will cover the drug's organotropism, its mechanism for targeting topoisomerase II, and its ability to stimulate CD8+ T cell cytotoxicity in pancreatic tumors. These findings support the company's broader development of Annamycin beyond its lead indication in acute myeloid leukemia (AML).

Counterparty
American Association for Cancer Research (AACR)
3:31 PM ET 8-K
M&A Deal Curaleaf Holdings, Inc. CURLF

Curaleaf Holdings Signs $11M M&A Deal with Aurora

Curaleaf Holdings has filed an application with the Alberta Securities Commission to halt Aurora's at-the-market (ATM) share issuance program during Curaleaf's pending acquisition offer. Curaleaf argues that Aurora's continued share sales at prices below the $4.00 offer price are an abusive defensive tactic that has increased the deal's cost by over $11 million and diluted shareholders by approximately 11%.

Value
$11M
Counterparty
Aurora
2:38 PM ET 8-K
Capital Raise Trilogy Metals Inc. TMQ

Trilogy Metals Capital Raise of $17.8M

Trilogy Metals closed a $17.8 million strategic equity investment from the U.S. Department of War, issuing 8,215,570 units at $2.17 per unit. The U.S. Government becomes an approximately 10% shareholder to advance domestic copper and cobalt supply from the Upper Kobuk Mineral Projects in Alaska.

Value
$17.8M
Counterparty
United States Department of War
12:15 PM ET 8-K
Capital Raise Allarity Therapeutics, Inc. ALLR

Allarity Therapeutics Capital Raise of $115M

Allarity Therapeutics announced that its newly formed SPAC, Allarity Acquisition Corp., has filed a Registration Statement for a proposed $100 million IPO ($115 million including overallotment). Allarity's subsidiary will act as the sponsor and is expected to own approximately 25% of the SPAC following the offering.

Value
$115M
Counterparty
Allarity Acquisition Corp.
12:15 PM ET 8-K
M&A Deal Crane Co CR

Crane Signs $240M M&A Deal with Trillium Flow Technologies

Crane Company has entered into a definitive agreement to acquire the U.S. pump business from First Reserve-backed Trillium Flow Technologies for approximately $240 million. The acquisition includes mission-critical brands such as Floway and Wemco, expanding Crane's Process Flow Technologies segment and its exposure to the municipal water and wastewater markets. The transaction is expected to close in the fourth quarter of 2026, adding a business with approximately $115 million in expected annual revenue.

Value
$240M
Counterparty
Trillium Flow Technologies
10:44 AM ET 8-K
M&A Deal Ondas Inc. ONDS

Ondas Signs $205M M&A Deal with Gate Technologies Ltd. and Bron Technologies sp. z.o.o

Ondas Inc. completed the acquisition of 100% of the share capital of Israel-based Gate Technologies Ltd. and its European affiliate Bron Technologies for $105 million in cash and approximately 10.7 million shares of common stock. The deal includes up to $185 million in contingent earn-out payments and expands Ondas' precision-strike platform with advanced electronic safe-and-arm and fuzing technology.

Value
$205M
Counterparty
Gate Technologies Ltd. and Bron Technologies sp. z.o.o
10:39 AM ET 8-K
M&A Deal Onconetix, Inc. ONCO

Onconetix Signs $5M M&A Deal with Realbotix, LLC

Onconetix provided a $5.0 million strategic bridge financing facility to Realbotix, LLC, the target of its previously announced pending acquisition. The facility is non-interest bearing and will be automatically cancelled and discharged upon the closing of the all-stock merger. This update supports the working capital needs of Realbotix as the parties work toward completing the transaction.

Value
$5M
Counterparty
Realbotix, LLC
Term
through Sept 2027
10:12 AM ET 8-K
Capital Raise Harvard Apparatus Regenerative Technology, Inc. HRGN

Harvard Apparatus Regenerative Technology Capital Raise of $2.84M

Harvard Apparatus Regenerative Technology closed a private placement of 2,703,727 shares of common stock at $1.05 per share for total proceeds of approximately $2.84 million. The transaction included a $717,911 debt-for-equity conversion by CEO Jerry (Junli) He, who cancelled outstanding bridge promissory notes in exchange for shares at the same offering price.

Value
$2.84M
Counterparty
Jerry (Junli) He and other private investors
9:30 AM ET 8-K
Regulatory Approval Biofrontera Inc. BFRI

Biofrontera Regulatory Approval

Biofrontera received FDA approval for its supplemental New Drug Application (sNDA) for Ameluz in combination with the BF-RhodoLED lamp series to treat superficial basal cell carcinoma. This marks the first and only photodynamic therapy approved in the U.S. for a skin cancer, significantly expanding the addressable market for the company's PDT platform.

“FDA approval of Ameluz for superficial basal cell carcinoma is a defining milestone for Biofrontera. Ameluz is now the first and only photodynamic therapy approved in the United States to treat a skin cancer, which sets our platform apart in medical dermatology and gives dermatologists an effective, non-surgical option for a very common tumor.”

Hermann Luebbert, Chief Executive Officer and Chairman of Biofrontera
9:19 AM ET 8-K
M&A Deal Baldwin Insurance Group, Inc. BWIN

Baldwin Insurance Group Signs $7.7B M&A Deal with Sequence Holdings and DFO Management

The Baldwin Insurance Group, Inc. has entered into a definitive agreement to be acquired and taken private by Sequence Holdings and DFO Management (the Dell Family Office) for $32.50 per share in cash. The transaction is valued at approximately $7.7 billion, including $3.1 billion of net debt, and represents an 88% premium to the company's unaffected closing price. Upon closing, expected in Q1 2027, Baldwin will become a privately held company with eligible employees retaining a minority equity stake.

Value
$7.7B
Counterparty
Sequence Holdings and DFO Management
9:19 AM ET 8-K
Capital Raise XBP Global Holdings, Inc. XBP

XBP Global Holdings Capital Raise of $6.05M

XBP Global Holdings entered into securities purchase agreements to raise approximately $6.05 million through a private placement of 2,275,245 shares of common stock. The offering included participation from company insiders, including the CEO, CFO, and affiliates of the Executive Chairman and a Board member, at prices ranging from $2.55 to $2.83 per share. Proceeds are intended for general corporate purposes, and the company has committed to filing a resale registration statement for the shares by September 22, 2026.

Value
$6.05M
Counterparty
Avenue Capital Group, HCI LLC, and other accredited investors
9:01 AM ET 8-K
Nasdaq/NYSE Compliance Notice Celularity Inc CELU

Celularity Nasdaq/NYSE Compliance Notice

Celularity Inc. has regained compliance with Nasdaq's minimum bid price and minimum market value of listed securities requirements. However, the company remains deficient regarding the timely filing of its periodic reports and is working to complete those filings to fully regain compliance.

Counterparty
The Nasdaq Stock Market LLC
8:55 AM ET 8-K
Nasdaq/NYSE Compliance Notice SmartKem, Inc. SMTK

SmartKem Nasdaq/NYSE Compliance Notice

SmartKem, Inc. has regained compliance with Nasdaq's minimum bid price requirement after its common stock maintained a closing bid price of at least $1.00 per share for 13 consecutive business days. The company had previously received a deficiency notice on March 5, 2026, and Nasdaq has now deemed the matter closed.

Counterparty
The Nasdaq Stock Market LLC
8:46 AM ET 8-K
M&A Deal Future Vision II Acquisition Corp. FVN

Future Vision II Acquisition M&A Deal with MicroTouch Technology Inc.

Future Vision II Acquisition Corp. issued a $65,000 promissory note to its sponsor, Hwei Super Speed Co., Ltd., to fund a one-month extension of its business combination deadline to October 13, 2026. The company confirmed it is continuing to pursue its previously announced merger with MicroTouch Technology Inc. and clarified that redemption funds from a prior extension event were paid at $11.03 per share.

Counterparty
MicroTouch Technology Inc.
Term
1 month
8:38 AM ET 8-K
Clinical Trial Data Summit Therapeutics Inc. SMMT

Summit Therapeutics Clinical Trial Data

Summit Therapeutics' partner Akeso presented updated Phase III HARMONi-2 trial data showing ivonescimab monotherapy significantly improved overall survival compared to pembrolizumab in PD-L1-positive advanced NSCLC. Ivonescimab reduced the risk of death by 27% (HR 0.73) and improved median overall survival by 8.2 months (30.8 months vs 22.6 months).

Counterparty
Akeso Inc.
8:38 AM ET 8-K
M&A Deal Bowman Consulting Group Ltd. BWMN

Bowman Consulting Group Signs $1B M&A Deal with Bernhard Capital Partners

Bowman Consulting Group announced the expiration of the 35-day 'go-shop' period under its previously announced merger agreement with Bernhard Capital Partners. No alternative acquisition proposals were received during the solicitation period, and the company is now subject to 'no-shop' provisions. The all-cash transaction, valued at approximately $1.0 billion or $43.00 per share, is expected to close in the fourth quarter of 2026.

Value
$1B
Counterparty
Bernhard Capital Partners
8:37 AM ET 8-K
Bankruptcy & Restructuring Cambium Networks Corp CMBMF

Cambium Networks Bankruptcy & Restructuring

Cambium Networks' subsidiary, Cambium Networks, Ltd, has entered administration in the UK, with administrators appointed to sell assets or wind up the business. In connection with this insolvency, the company reduced its global workforce by 260 employees (53.6%) and terminated the role of Senior VP of Products, Vibhu Vivek.

Counterparty
RSM UK Restructuring Advisory LLP
8:27 AM ET 8-K
Capital Raise Enbridge Inc ENB

Enbridge Capital Raise

Enbridge Inc. completed a bought deal public offering of 44,735,000 common shares, including the full exercise of an over-allotment option. The offering generated gross proceeds of approximately CDN$3.0 billion. The transaction was conducted through a syndicate of underwriters led by RBC Dominion Securities and CIBC World Markets.

Counterparty
RBC Dominion Securities Inc. and CIBC World Market Inc.
8:11 AM ET 8-K
M&A Deal Nomadar Corp. NOMA

Nomadar Signs $2M M&A Deal with Fox Soccer Academy

Nomadar Corp. has entered into a definitive equity purchase agreement to acquire a majority interest in Fox Soccer Academy (FSA), which operates youth soccer programs in New York, North Carolina, the UK, and Austria. The consideration includes a $2 million base cash payment and the issuance of Class B Units in a subsidiary representing a 49% retained interest by the sellers. The deal expands Nomadar's international sports development platform by integrating FSA's Premier League-inspired curriculum with Nomadar's existing Spanish football initiatives.

Value
$2M
Counterparty
Fox Soccer Academy
8:03 AM ET 8-K
Clinical Trial Data Definium Therapeutics, Inc. DFTX

Definium Therapeutics Clinical Trial Data

Definium Therapeutics announced positive topline results from its Phase 3 Panorama study of DT120 ODT for the treatment of generalized anxiety disorder (GAD). The study met its primary endpoint with a statistically significant reduction in HAM-A scores compared to placebo (p<0.0001) and was generally well tolerated. The company plans to file an NDA in the first half of 2027 following a pre-NDA meeting with the FDA in Q4 2026.

8:02 AM ET 8-K
Divestiture Thryv Holdings, Inc. THRY

Thryv Holdings Divestiture to Coldwater YP, LLC for $142M

Thryv Holdings, Inc. has entered into a definitive agreement to sell its print directories business in the U.S., Australia, and New Zealand to Coldwater YP, LLC for $142 million in cash. The company intends to use the proceeds to reduce debt and focus resources on its AI-powered SaaS Growth Platform. The transaction is expected to close in the fourth quarter of 2026.

Value
$142M
Counterparty
Coldwater YP, LLC (an affiliate of Carolwood, L.P.)
8:01 AM ET 8-K
Capital Raise Cabaletta Bio, Inc. CABA

Cabaletta Bio Capital Raise of $128M

Cabaletta Bio announced the completion of warrant exercises from its June 2025 public offering, resulting in total aggregate gross proceeds of approximately $128.2 million. The warrants, which had an exercise price of $2.50 per share, expired on September 12, 2026, with the vast majority of exercises occurring between July 1, 2026, and the expiration date.

Value
$128M
8:01 AM ET 8-K
M&A Deal Perdoceo Education Corp PRDO

Perdoceo Education Signs $224M M&A Deal with South University Savannah, LLC

Perdoceo Education Corporation entered into a definitive agreement to acquire 100% of South University for an initial cash payment of $150 million, plus $18 million in deferred consideration and up to $56 million in performance-based earn-outs. South University is a leading health sciences-focused institution with 11 campus locations and approximately 10,500 students, generating $291 million in 2025 revenue. The transaction is expected to close as early as April 2027 and will expand Perdoceo's graduate health sciences and academic program offerings.

Value
$224M
Counterparty
South University Savannah, LLC
8:01 AM ET 8-K
Clinical Trial Data Telomir Pharmaceuticals, Inc. TELO

Telomir Pharmaceuticals Clinical Trial Data

Telomir Pharmaceuticals announced positive preclinical in-vitro research findings demonstrating that its compound Telomir-Zn inhibited cell growth in both human and canine osteosarcoma models. The study, conducted with The Ohio State University, showed consistent anti-tumor activity at low drug concentrations, supporting a potential parallel development pathway for veterinary and human oncology indications.

Counterparty
The Ohio State University College of Veterinary Medicine
8:01 AM ET 8-K
Regulatory Approval Scholar Rock Holding Corp SRRK

Scholar Rock Holding Regulatory Approval

Scholar Rock received FDA approval for ISEMBYLD (apitegromab-mstn) for the treatment of spinal muscular atrophy (SMA) in adults and children aged 2 and older. This marks the first and only muscle-targeted treatment approved for SMA, representing a significant therapeutic breakthrough for the company's myostatin biology platform.

Earnings call
Sep 14, 2026, 8:00 AM ET

“Today’s FDA approval of ISEMBYLD marks a defining moment for the SMA community as we now launch the world’s first-ever muscle targeted treatment for children and adults living with SMA in the U.S. After decades of failed industry-wide efforts to unlock the potential of myostatin inhibition, Scholar Rock has delivered a therapeutic breakthrough with ISEMBYLD.”

David L. Hallal, Chairman and Chief Executive Officer of Scholar Rock
7:59 AM ET 8-K
M&A Deal AirJoule Technologies Corp. AIRJ

AirJoule Technologies Signs $27M M&A Deal with Bitsink LLC

AirJoule Technologies acquired 100% of Bitsink LLC, a manufacturer of cooling and power infrastructure for AI and high-density data centers, for $18 million in cash and $9 million in common stock. The deal includes up to $40 million in additional performance-based earnout payments through 2029, significantly expanding AirJoule's footprint in the AI and HPC infrastructure market.

Value
$27M
Counterparty
Bitsink LLC
Earnings call
Sep 14, 2026, 8:30 AM ET
7:41 AM ET 8-K
Nasdaq/NYSE Compliance Notice Texas Capital Bancshares Inc TXCP

Texas Capital Bancshares Nasdaq/NYSE Compliance Notice

Texas Capital Bancshares is voluntarily withdrawing its common and preferred stock listings from Nasdaq to transfer them to the newly formed Texas Stock Exchange (TXSE). Trading is expected to begin on the TXSE on October 8, 2026, with a subsequent ticker symbol change from TCBI to TXCP scheduled for November 9, 2026.

Counterparty
Texas Stock Exchange LLC

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.